NasdaqGM - Delayed Quote • USD Horizon Therapeutics Public Lim (HZNP) Follow 116.30 0.00 (0.00%) As of April 4 at 4:00 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Rule 17(e) Announcement - Horizon Therapeutics plc DUBLIN, October 06, 2023-- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) DUBLIN, October 03, 2023--IRISH TAKEOVER PANEL Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023 DUBLIN, October 02, 2023--Horizon Therapeutics plc announces new UPLIZNA data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2023. New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023. Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry DUBLIN, September 26, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing. FTC chair targets deals that have fallen in agency's 'blind spots' FTC chair Lina Khan has her sights focused on challenging mergers & acquisitions in the healthcare and tech sectors, specifically those valued under $100 million. Khan argues that these mergers can snowball into larger monopolies when left unchecked. Senior Reporter for Yahoo Finance Anjalee Khemlani joins to breakdown Lina Khan's recent statement at the Oliver Wyman Health Innovation Summit in Chicago. Healthcare: FTC Chair Lina Khan to crack down on 'below radar' deals FTC Chair Lina Khan wants to help create more competition in the market and avoid monopolies. Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List DUBLIN, September 19, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named to the list and the company’s fourth time ranking No. 1. Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive Horizon Therapeutics plc ("Horizon") Rule 2.12 Announcement DUBLIN, September 06, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on September 5, 2023, Horizon’s issued ordinary share capital is comprised of 229,214,753 ordinary shares, nominal value $0.0001 per share (the "Ordinary Shares") and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement DUBLIN, September 05, 2023--Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition THOUSAND OAKS, Calif., & DUBLIN, September 01, 2023--AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Is This the Green Light Biotech Stocks Have Been Waiting For? It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics. FTC suspends challenge to Amgen-Horizon Therapeutics deal The Federal Trade Commission is suspending its challenge to Amgen's (AMGN) $27.8 billion bid to acquire Horizon Therapeutics (HZNP). The FTC is concerned Amgen will be able to bundle its products to a couple of Horizon's, giving it an advantage over rivals. It's a notion Amgen rejects. The FTC is pausing its challenge in hopes of reaching a settlement that would allow the deal to close. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks the story down. Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups DUBLIN, August 23, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient groups who worked with Horizon also ranked the company first in 10 of the 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships (communications, long-term support and ease of working) and services "bey Horizon Therapeutics plc - Rule 2.12 Announcement DUBLIN, August 09, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on June 30, 2023, Horizon’s issued ordinary share capital is comprised of 228,939,027 ordinary shares, nominal value $0.0001 per share (the "Ordinary Shares") and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results DUBLIN, August 08, 2023--Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results Amgen raises full-year earnings and revenue outlook Investing.com -- Shares in Amgen (NASDAQ:AMGN) rose in premarket U.S. trading on Friday after the U.S. biotech company improved its annual earnings and revenue forecast, and said it expects to close its planned multibillion-dollar acquisition of Horizon Therapeutics (NASDAQ:HZNP) by mid-December. Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients DUBLIN, July 27, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis™ Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities. Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint DUBLIN, July 21, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which was the proportion of patients to achieve a British Isles Lupus Assessment Group (BILAG) 2004 Index-based Combined Lupus Assessment (BICLA) response and an oral glucocorticoid (OGC) dose of ≤7.5 mg/day (prednisone equivalent), w
